MedTrace Logo

Oral Misoprostol for Cervical Priming Before Hysteroscopy

NCT02159911 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 84

Last updated 2014-06-10

No results posted yet for this study

Summary

A randomized, double blind study to compare 200 and 400 mcg misoprostol for cervical preparation before hysteroscopy.

Conditions

  • Cervical Laceration
  • Adverse Effects

Interventions

DRUG

Misoprostol administered orally one hour before surgery

Closed and numbered envelopes, containing a capsule with either 200mcg or 400mcg of misoprostol were randomly distributed to the patients. Each envelope was coded randomly and only the pharmaceutical department of the hospital knew the content of these envelopes and kept a list of their codes. The misoprostol was administered by the floor nurse, per-os to the patient one hour before hysteroscopy with a small amount of water. The number on the envelope was noted by the nurse on the document relative to the patient. Hence, the patient, the physician performing the biopsy, the nurse and the research associate did not know the exact dose of misoprostol that was ingested by the patient.

Sponsors & Collaborators

  • Saint-Joseph University

    lead OTHER

Principal Investigators

  • Assaad K Kesrouani, MD · Saint-Joseph University

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Primary Completion
2004-11-30
Completion
2004-11-30

Countries

  • Lebanon

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02159911 on ClinicalTrials.gov